The market is segmented based on , By Drug Classification (Prolia, Xgeva, and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centres, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2030.
.
The Global Denosumab Market size was valued at USD 2892.17 USD Million in 2022.
The Global Denosumab Market is projected to grow at a CAGR of 11.9% during the forecast period of 2023 to 2030.
The major players operating in the market include Merck &, Co.Inc ,Amneal Pharmaceutical Inc ,Teva Pharmaceutical Industries Ltd ,Zydus Cadila ,Novartis Ag ,Pfizer Inc ,Astrazeneca ,Glaxosmithkline Plc ,Bristol Myers Squibb Company ,Johnson &, Johnson Service Inc ,F. Hoffmann- La Roche Ltd ,Bayer AG ,Amgen Inc ,Sanofi ,Biogen ,Regeneron Pharmaceuticals Inc ,Eli Lilly the Company ,AbbiVie Inc ,Mylan N.V. ,Eisai Co.Ltd .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America.
Corporate Email ID Only (Avoid Using Generic mail ID such as Gmail)
Consent Preferences
We use cookies to improve your experience We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies. Cookie Notice.
The data presented is for visualization purposes only and may not reflect actual results.